
Prenetics Group Limited, a global leader in genomic and diagnostic testing, has introduced a novel, non-invasive, at-home screening test—ColoClear by Circle (ColoClear)—for detecting early signs of colorectal cancer. Colorectal cancer is the second most common cancer in Hong Kong, accounting for 15.8% of total new cancers in 2019. Combining advanced stool DNA technology with a faecal immunochemical test (FIT), the revolutionary test is the first line of defence against one of the most preventable cancers, which can be treated in 90% of cases when detected early.
ColoClear has been launched in partnership with New Horizon Health, a biotechnology pioneer in the early detection of cancer screening tools. The novel screening test uses advanced technology to detect multiple DNA biomarkers and blood cells in human stool.
In the ColoClear clinical studies, a total of 4,758 subjects were validated in 8 clinical institutions in China. The age subjects were between 40 to 75, with a mean of 55.69±8.69. At total of 46.26% of subjects were male.
Among all patient samples, 605 cases of colorectal cancer and 375 cases of advanced adenoma were confirmed by colonoscopy and/or pathological examination. Clinical trial results showed that the sensitivity of the ColoClear was 95.54% (95%CI: 93.89%, 97.18%), including 96.8% Stage I, 97.5% Stage II, 96.2% Stage III and 96.4% for Stage IV CRC. The assay also demonstrated 63.47% (95%CI: 58.59%, 68.34%) sensitivity for advanced adenoma; the screening specificity for colorectal cancer and advanced adenoma was 87.08% (95%CI: 86.00%, 88.16%); and Negative Predictive Value of colorectal cancer screening was 99.6% (95%CI: 99.2%, 99.7%). Given Coloclear’s strong test performance, it is the only cancer screening test approved by the National Medical Products Administration (NMPA).
Danny Yeung, CEO at and Co-Founder of Prenetics, stated, “We are extremely excited with the launch of ColoClear in Hong Kong, enabling an easy alternative to Colonoscopy. ColoClear will play a key role in helping to reduce cases and mortality from colorectal cancer in the city. ColoClear is a clear scientific breakthrough that can be expanded across Southeast Asia, with a population of more than 600 million people. As in the case with Cologuard in the USA, working with insurance companies would have a major impact on adoption and we have begun discussions with large regional insurance companies.”
“New Horizon Health and Prenetics share the same vision in healthcare. Prevention and early detection, home-based healthcare, and individualized service have become the major trends in the war on cancer around the globe. We have confidence that with our joint efforts, ColoClear will become a benchmark for Asian innovation, raising awareness in cancer screening while saving many lives,” said YeQing Zhu, CEO at New Horizon Health.
Lifestyle factors associated with a busy city like Hong Kong, such as lack of regular exercise, a diet low in fruit and vegetables and alcohol consumption may contribute to an increased risk of colorectal cancer. According to the Hong Kong Cancer Registry of the Hospital Authority, colorectal cancer has been ranked among the top two high-incidence cancers in Hong Kong since 2012, while being the second most common cause of cancer death. About 1 in every 6 to 7 new cancer patients suffers from colorectal cancer. More than half of detected cases are found in late stage with a low survival rate. However, if it is found at an early stage, colorectal cancer has a survival rate of over 90%.
Prenetics is partnering with leading medical groups in Hong Kong to make colorectal cancer screening accessible and convenient to the Hong Kong people. The test is priced at HK $3,000. Individuals can visit the official website (www.hicircle.com/coloclear) to book a physical or virtual medical consultation with Prenetics’s partner clinics, and collect the stool sample in the comfort of their own homes. Upon sending the sample via courier for laboratory testing, users will receive their results within five business days.


Archive
- October 2024(44)
- September 2024(94)
- August 2024(100)
- July 2024(99)
- June 2024(126)
- May 2024(155)
- April 2024(123)
- March 2024(112)
- February 2024(109)
- January 2024(95)
- December 2023(56)
- November 2023(86)
- October 2023(97)
- September 2023(89)
- August 2023(101)
- July 2023(104)
- June 2023(113)
- May 2023(103)
- April 2023(93)
- March 2023(129)
- February 2023(77)
- January 2023(91)
- December 2022(90)
- November 2022(125)
- October 2022(117)
- September 2022(137)
- August 2022(119)
- July 2022(99)
- June 2022(128)
- May 2022(112)
- April 2022(108)
- March 2022(121)
- February 2022(93)
- January 2022(110)
- December 2021(92)
- November 2021(107)
- October 2021(101)
- September 2021(81)
- August 2021(74)
- July 2021(78)
- June 2021(92)
- May 2021(67)
- April 2021(79)
- March 2021(79)
- February 2021(58)
- January 2021(55)
- December 2020(56)
- November 2020(59)
- October 2020(78)
- September 2020(72)
- August 2020(64)
- July 2020(71)
- June 2020(74)
- May 2020(50)
- April 2020(71)
- March 2020(71)
- February 2020(58)
- January 2020(62)
- December 2019(57)
- November 2019(64)
- October 2019(25)
- September 2019(24)
- August 2019(14)
- July 2019(23)
- June 2019(54)
- May 2019(82)
- April 2019(76)
- March 2019(71)
- February 2019(67)
- January 2019(75)
- December 2018(44)
- November 2018(47)
- October 2018(74)
- September 2018(54)
- August 2018(61)
- July 2018(72)
- June 2018(62)
- May 2018(62)
- April 2018(73)
- March 2018(76)
- February 2018(8)
- January 2018(7)
- December 2017(6)
- November 2017(8)
- October 2017(3)
- September 2017(4)
- August 2017(4)
- July 2017(2)
- June 2017(5)
- May 2017(6)
- April 2017(11)
- March 2017(8)
- February 2017(16)
- January 2017(10)
- December 2016(12)
- November 2016(20)
- October 2016(7)
- September 2016(102)
- August 2016(168)
- July 2016(141)
- June 2016(149)
- May 2016(117)
- April 2016(59)
- March 2016(85)
- February 2016(153)
- December 2015(150)